Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

Pelacarsen is in a cardiovascular outcomes trial in patients with elevated Lp(a) levels, with results expected in 2025, while pivotal results with OAV101 IT – a follow-up to Novartis' spinal ...

Bearish flow noted in Novartis (NVS) with 1,936 puts trading, or 3x expected. Most active are Apr-25 105 puts and Apr-25 110 puts, with total ...

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D. In this Pharmaceutical Executive video interview, ...

In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung cancer, both as monotherapy and in combination therapies. These results, ...

Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...

A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions ...

On March 26, 2025, the new drug application (NDA) for diazoxide choline extended-release tablets (VYKAT XR; Soleno Therapeutics) was approved by the FDA to treat hyperphagia among individuals aged 4 ...